Stephen A Hahn

6519488, Feb 11, 2003

Aug 27, 2001

09/940336

Bruce H. KenKnight - Maple Grove MN
Jay A. Warren - North Oaks MN
Stephen John Hahn - Shoreview MN

Cardiac Pacemakers, Inc. - St. Paul MN

A61B 504

600372, 606 41, 606194, 606198

A first electrode is positioned within an artery proximate an implanted intravascular stent. A second electrode is positioned at a separate location relative the position of the first electrode. Electrical energy is then delivered between the first and the second electrodes to produce an electrical field adjacent the implanted intravascular stent. When a intravascular stent is implanted in a coronary artery, the delivery of the electrical energy is coordinated to cardiac cycles detected in sensed cardiac signals, where the delivery of the electrical energy between the first electrode and the second electrode occurs during a predetermined portion of the cardiac cycle.

6648881, Nov 18, 2003

Aug 27, 2001

09/940337

Bruce H. KenKnight - Maple Grove MN
Jay A. Warren - North Oaks MN
Stephen John Hahn - Shoreview MN

Cardiac Pacemakers, Inc. - St. Paul MN

A61B 1804

606 32, 606 41, 606194, 606198, 600372, 600381

A first electrode is positioned within an artery proximate an implanted intravascular stent. A second electrode is positioned at a separate location relative the position of the first electrode. Electrical energy is then delivered between the first and the second electrodes to produce an electrical field adjacent the implanted intravascular stent. When a intravascular stent is implanted in a coronary artery, the delivery of the electrical energy is coordinated to cardiac cycles detected in sensed cardiac signals, where the delivery of the electrical energy between the first electrode and the second electrode occurs during a predetermined portion of the cardiac cycle.

6775572, Aug 10, 2004

Oct 25, 2001

10/037302

Qingsheng Zhu - Little Canada MN
Stephen John Hahn - Shoreview MN
Steven D. Girouard - Woodbury MN

Cardiac Pacemakers, Inc. - St. Paul MN

A61N 1365

607 14

A method and system for delivering anti-tachycardia pacing is disclosed. A cardiac rhythm management device, such as an implantable pacemaker having anti-tachycardia pacing capability, delivers anti-tachycardia pacing therapy in accordance with an anti-tachycardia pacing protocol upon detection of a terminable arrhythmia. The anti-tachycardia pacing is delivered as a burst of one or more pacing pulses at a specified coupling interval after a sensed ventricular polarization. By sensing if an evoked potential occurs, the device can determine whether or not the anti-tachycardia pacing burst has captured the ventricle and can adjust the coupling interval and/or other parameters accordingly.

6939345, Sep 6, 2005

Mar 26, 2003

10/397623

Bruce H. KenKnight - Maple Grove MN, US
Jay A. Warren - North Oaks MN, US
Stephen John Hahn - Shoreview MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

A61B018/04

606 32, 606 41, 606194, 606198, 600372, 600381

A first electrode is positioned within an artery proximate an implanted intravascular stent. A second electrode is positioned at a separate location relative the position of the first electrode. Electrical energy is then delivered between the first and the second electrodes to produce an electrical field adjacent the implanted intravascular stent. When a intravascular stent is implanted in a coronary artery, the delivery of the electrical energy is coordinated to cardiac cycles detected in sensed cardiac signals, where the delivery of the electrical energy between the first electrode and the second electrode occurs during a predetermined portion of the cardiac cycle.

6953868, Oct 11, 2005

Apr 26, 2004

10/831869

Nicole K. Boaen - Minneapolis MN, US
Marc A. Hillmyer - Minneapolis MN, US
Stephen F. Hahn - Midland MI, US

Dow Global Technologies Inc. - Midland MI
Regents of the University of Minnesota - Minneapolis MN

C07C031/18
C08F138/00

568852, 568857, 5689105, 526285

The present invention is a method for oxyfunctionalizing, that is, introducing oxygen functionality to, a polyolefin such as polypropylene and poly(ethylene-alt-propylene). The polyolefin is contacted with an oxygen source such as a persulfate and catalytic amounts of a metal porphyrin complex under mild conditions to yield an oxyfunctionalized polymer that has a polydispersity that is very similar to that of the starting polymer.

7376464, May 20, 2008

Aug 9, 2004

10/914495

Qingsheng Zhu - Little Canada MN, US
Stephen John Hahn - Shoreview MN, US
Steven D. Girouard - Woodbury MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

A61N 1/00

607 27

A method and system for delivering anti-tachycardia pacing is disclosed. A cardiac rhythm management device, such as an implantable pacemaker having anti-tachycardia pacing capability, delivers anti-tachycardia pacing therapy in accordance with an anti-tachycardia pacing protocol upon detection of a terminable arrhythmia. The anti-tachycardia pacing is delivered as a burst of one or more pacing pulses at a specified coupling interval after a sensed ventricular polarization. By sensing if an evoked potential occurs, the device can determine whether or not the anti-tachycardia pacing burst has captured the ventricle and can adjust the coupling interval and/or other parameters accordingly.

7844331, Nov 30, 2010

Dec 20, 2005

11/312082

Dan Li - Shoreview MN, US
Gerrard M. Carlson - Champlin MN, US
Stephen J. Hahn - Shoreview MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

A61N 1/365

607 14, 607 24, 600513

A cardiac rhythm management (CRM) system includes an implantable medical device that delivers anti-tachyarrhythmia therapies including anti-tachyarrhythmia pacing (ATP) and at least one hemodynamic sensor that senses a hemodynamic signal. When a tachyarrhythmia episode is detected, the CRM system analyzes the hemodynamic signal to determine whether and/or when to deliver an ATP. In one embodiment, a hemodynamic parameter extracted from the hemodynamic signal is used to predict the potential effectiveness of ATP in terminating the detected tachyarrhythmia episode. In another embodiment, a characteristic feature detected from the hemodynamic signal is used to determine an ATP window during which a delivery of ATP is initiated.

8260423, Sep 4, 2012

Jul 16, 2009

12/504450

Stephen J. Hahn - Shoreview MN, US
Yanting Dong - Shoreview MN, US
Haresh G. Sachanandani - Culver City CA, US
Kenneth P. Hoyme - Plymouth MN, US
James O. Gilkerson - Stillwater MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

A61N 1/00

607 32, 607 30, 607 59, 607 60

A method of collecting patient event information from a cardiac rhythm management system (CRM system) is described, where the CRM system includes a cardiac rhythm management device (CRM device) and an external interface device. The method includes the steps of initiating a transmission session wherein the interface device communicates with the CRM device, prompting a user of the CRM system to select a reason for the transmission session, inputting the selected reason for the transmission session to the interface device, and storing the selected reason for the transmission session and timestamp information for the transmission session.